Merck’s patent fortress, a SCOTUS skinny label case, monopoly menus, and more
Year-in-review: How the USPTO was Hallowed Out in 2025
New survey shows Americans want patent reform
Keytruda Qlex: Where’s the invention?
Two bipartisan bills target patent abuse
Still Overpatented, Still Overpriced
Merck’s Scheme to Product Hop Keytruda
We Need More Drug Patent Data
Five Patent Predictions for 2025
The Year in Patent Reform